Analysts See $-0.36 EPS for Oxford Immunotec Global PLC (OXFD); Essex (KEYW)’s Sentiment Is 1.96

February 10, 2018 - By Stephen Andrade

Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report $-0.36 EPS on February, 27.They anticipate $0.14 EPS change or 63.64% from last quarter’s $-0.22 EPS. After having $-0.24 EPS previously, Oxford Immunotec Global PLC’s analysts see 50.00% EPS growth. The stock increased 1.05% or $0.12 during the last trading session, reaching $11.5. About 198,299 shares traded or 0.78% up from the average. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since February 10, 2017 and is uptrending. It has outperformed by 37.56% the S&P500.

The KEYW Holding Corporation, through its subsidiaries, provides engineering and technology solutions to support the collection, processing, analysis, and dissemination of information across the intelligence, cyber, and counterterrorism communities. The company has market cap of $329.23 million. The Company’s solutions are designed to respond to meet the critical needs for agile intelligence and to assist the U.S. government national security priorities through various cyber activities and training, geospatial intelligence, cloud and data analytics, engineering, and intelligence analysis and activities offerings. It currently has negative earnings. The Company’s products include electro-optical, hyperspectral and synthetic aperture radar sensors, and other products.

Since August 15, 2017, it had 0 insider purchases, and 3 insider sales for $1.13 million activity. 9,739 shares valued at $157,171 were sold by Edwardson Peter on Tuesday, August 15. On Monday, October 2 Wrighton-Smith Peter sold $922,933 worth of Oxford Immunotec Global PLC (NASDAQ:OXFD) or 55,000 shares. SANDBERG RICHARD A sold $47,460 worth of Oxford Immunotec Global PLC (NASDAQ:OXFD) on Friday, September 1.

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.14, from 1.27 in 2017Q2. It dropped, as 3 investors sold Oxford Immunotec Global PLC shares while 27 reduced holdings. 12 funds opened positions while 22 raised stakes. 22.51 million shares or 13.08% more from 19.91 million shares in 2017Q2 were reported. Royal Financial Bank Of Canada holds 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD) or 2,018 shares. Perceptive Lc reported 465,356 shares. Eam Limited Company reported 120,397 shares stake. Prelude Cap Management Limited Co has 0.03% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 17,482 shares. Endurant Cap L P accumulated 3.72% or 731,509 shares. Waddell Reed Fin Inc accumulated 227,400 shares or 0.01% of the stock. Tiaa Cref Invest Management Ltd Liability Corp accumulated 84,854 shares. Legal General Public Limited Co holds 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD) or 7,275 shares. Barclays Public Ltd Com accumulated 524 shares. Moreover, Axa has 0.06% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). Nationwide Fund Advsrs has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). Keybank Association Oh, Ohio-based fund reported 40,244 shares. Serv Automobile Association stated it has 162,500 shares or 0.01% of all its holdings. Natl Bank Of America De reported 0% stake. Fosun Interest invested in 237,783 shares.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $295.03 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. Cowen & Co maintained the shares of OXFD in report on Tuesday, October 31 with “Buy” rating. The firm has “Buy” rating given on Tuesday, October 31 by Robert W. Baird. The firm has “Buy” rating given on Thursday, October 19 by Robert W. Baird. The stock has “Buy” rating by BTIG Research on Thursday, September 28. The rating was maintained by Piper Jaffray on Monday, January 8 with “Buy”. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) has “Buy” rating given on Wednesday, July 19 by Cowen & Co. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 16 report. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) on Wednesday, September 27 with “Buy” rating. The firm has “Buy” rating by Cowen & Co given on Monday, January 22.

Snyder Capital Management L P holds 0.63% of its portfolio in The KEYW Holding Corporation for 1.66 million shares. Stephens Investment Management Group Llc owns 2.44 million shares or 0.43% of their US portfolio. Moreover, Elk Creek Partners Llc has 0.41% invested in the company for 866,369 shares. The Georgia-based Concourse Capital Management Llc has invested 0.21% in the stock. Oak Ridge Investments Llc, a Illinois-based fund reported 631,200 shares.

The stock increased 4.04% or $0.26 during the last trading session, reaching $6.69. About 1.08 million shares traded or 98.35% up from the average. The KEYW Holding Corporation (KEYW) has risen 6.38% since February 10, 2017 and is uptrending. It has underperformed by 10.32% the S&P500.

Analysts await The KEYW Holding Corporation (NASDAQ:KEYW) to report earnings on March, 14. They expect $-0.03 EPS, up 62.50% or $0.05 from last year’s $-0.08 per share. After $0.03 actual EPS reported by The KEYW Holding Corporation for the previous quarter, Wall Street now forecasts -200.00% negative EPS growth.